Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system

BACKGROUND: In the USA, oral nirmatrelvir–ritonavir is authorised for use in patients aged 12 years or older with mild-to-moderate COVID-19 who are at risk of progression to severe disease and hospitalisation. We aimed to establish the effectiveness of nirmatrelvir–ritonavir in preventing hospital a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewnard, Joseph A, McLaughlin, John M, Malden, Debbie, Hong, Vennis, Puzniak, Laura, Ackerson, Bradley K, Lewin, Bruno J, Kim, Jeniffer S, Shaw, Sally F, Takhar, Harpreet, Jodar, Luis, Tartof, Sara Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081864/
https://www.ncbi.nlm.nih.gov/pubmed/36933565
http://dx.doi.org/10.1016/S1473-3099(23)00118-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081864/
https://www.ncbi.nlm.nih.gov/pubmed/36933565
http://dx.doi.org/10.1016/S1473-3099(23)00118-4

Ejemplares similares